title: Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for allergic airways disease.
abstract: We evaluated the extent to which individual versus combination treatments that specifically target airway epithelial damage [trefoil factor-2 (TFF2)], airway fibrosis [serelaxin (RLX)] or airway inflammation [dexamethasone (DEX)] reversed the pathogenesis of chronic allergic airways disease (AAD).
  
  
  
  Following induction of ovalbumin (OVA)-induced chronic AAD in 6–8 week female Balb/c mice, animals were i.p. administered naphthalene (NA) on day 64 to induce epithelial damage, then received daily intranasal administration of RLX (0.8 mg·mL(−1)), TFF2 (0.5 mg·mL(−1)), DEX (0.5 mg·mL(−1)), RLX + TFF2 or RLX + TFF2 + DEX from days 67–74. On day 75, lung function was assessed by invasive plethysmography, before lung tissue was isolated for analyses of various measures. The control group was treated with saline + corn oil (vehicle for NA).
  
  
  
  OVA + NA-injured mice demonstrated significantly increased airway inflammation, airway remodelling (AWR) (epithelial damage/thickness; subepithelial myofibroblast differentiation, extracellular matrix accumulation and fibronectin deposition; total lung collagen concentration), and significantly reduced airway dynamic compliance (cDyn). RLX + TFF2 markedly reversed several measures of OVA + NA-induced AWR and normalized the reduction in cDyn. The combined effects of RLX + TFF2 + DEX significantly reversed peribronchial inflammation score, airway epithelial damage, subepithelial extracellular matrix accumulation/fibronectin deposition and total lung collagen concentration (by 50–90%) and also normalized the reduction of cDyn.
  
  
  
  Combining an epithelial repair factor and anti-fibrotic provides an effective means of treating the AWR and dysfunction associated with AAD/asthma and may act as an effective adjunct therapy to anti-inflammatory corticosteroids
authors.affiliation: Fibrosis Laboratory, Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Vic., Australia.
authors.forename: K P
authors.initials: KP
authors.lastname: Patel
authors.affiliation: Murdoch Children's Research Institute, University of Melbourne, Vic., Australia.|Department of Paediatrics, University of Melbourne, Vic., Australia.
authors.forename: A S
authors.initials: AS
authors.lastname: Giraud
authors.affiliation: Fibrosis Laboratory, Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Vic., Australia.
authors.forename: C S
authors.initials: CS
authors.lastname: Samuel
authors.affiliation: Fibrosis Laboratory, Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Vic., Australia.|Respiratory Pharmacology Laboratory, Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Vic., Australia.
authors.forename: S G
authors.initials: SG
authors.lastname: Royce
mesh_terms: D000818:Animals; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005355:Fibrosis / Q000517:prevention & control; D006967:Hypersensitivity / Q000150:complications / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D000071164:Trefoil Factor-2 / Q000187:drug effects
chemical_list: C481546:TFF2 protein, mouse; D000071164:Trefoil Factor-2; D003907:Dexamethasone